Source: Eur Respir J, 52 (6) 1801127; 10.1183/13993003.01127-2018
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Rahul Shrimanker, Ian D. Pavord, Steve Yancey, Liam G. Heaney, Ruth H. Green, Peter Bradding, Beverley Hargadon, Chris E. Brightling, Andrew J. Wardlaw, Pranabashis Haldar. Exacerbations of severe asthma in patients treated with mepolizumab. Eur Respir J, 52 (6) 1801127; 10.1183/13993003.01127-2018

Member's Comments

No comment yet.

Related content which might interest you: Evolution of patients with severe asthma treated with mepolizumab Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Long-term effect of roflumilast on exacerbations in patients with severe to very severe COPD Source: Eur Respir J 2006; 28: Suppl. 50, 526s Year: 2006 Severe outcomes of COVID-19 among patients with COPD and asthma Source: ERJ Open Res, 7 (1) 00594-2020; 10.1183/23120541.00594-2020 Year: 2021 Impact of omalizumab in patients with severe asthma Source: Annual Congress 2009 - Aspects of uncontrolled asthma Year: 2009 Exacerbations of asthma and treatment Source: International Congress 2018 – PG1 Asthma and chronic obstructive pulmonary disease Year: 2018 Montelukast as add-on therapy in severe noninfectious COPD exacerbations Source: Eur Respir J 2003; 22: Suppl. 45, 241s Year: 2003 Add-on omalizumab therapy reduces clinically significant and severe asthma exacerbations, and improves FEV1 in patients with severe persistent allergic asthma irrespective of age Source: Eur Respir J 2005; 26: Suppl. 49, 48s Year: 2005 Mepolizumab efficacy in patients with severe eosinophilic asthma and bronchiectasis Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Oral montelukast in patients with acute severe asthma Source: Annual Congress 2007 - Recent advances in our understanding of the treatment of asthma Year: 2007 Omalizumab treatment reduces asthma exacerbations in children with moderate or severe persistent asthma Source: International Congress 2017 – Paediatric asthma: treatment modalities and behavioural issues Year: 2017 Markers of T2-inflammation in patients with severe asthma and concomitant COPD Source: Virtual Congress 2020 – News on clinical evaluation of bronchiectasis, cough and inflammatory disease Year: 2020 Real-life treatment of severe eosinophilic asthma with mepolizumab Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Ceruloplasmine efficacy in patients with asthma exacerbations Source: Annual Congress 2011 - Novel mechanisms in lung injury Year: 2011 Exacerbation of respiratory symptoms in COPD patients may not be exacerbations of COPD Source: Eur Respir J 2013; 41: 993-995 Year: 2013 Clinical response to mepolizumab in patients with severe eosinophilic asthma Source: International Congress 2019 – Understanding, monitoring and targeting severe asthma Year: 2019 Anti-IgE therapy with omalizumab decreases exacerbations in patients with poorly controlled moderate-to-severe allergic asthma Source: Eur Respir J 2003; 22: Suppl. 45, 203s Year: 2003 Triple therapy for all patients with severe symptomatic COPD at risk of exacerbations Source: Eur Respir J, 53 (4) 1900147; 10.1183/13993003.00147-2019 Year: 2019 Predictors of severe exacerbations in patients with moderate and severe asthma Source: International Congress 2018 – Determinants and monitoring of asthma control Year: 2018 Exacerbations of COPD and treatment Source: International Congress 2018 – PG1 Asthma and chronic obstructive pulmonary disease Year: 2018 Endotypes of severe allergic asthma patients who clinically benefit from Anti-IgE therapy Source: International Congress 2018 – Studying novel biomarkers in asthma and COPD Year: 2018